Sarcopenia in patients receiving TIPS is independently associated with increased risk of complications and mortality.

Complications Dysfunction Portosystemic shunt Sarcopenia

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
28 Oct 2024
Historique:
received: 16 07 2024
revised: 16 09 2024
accepted: 11 10 2024
medline: 30 10 2024
pubmed: 30 10 2024
entrez: 29 10 2024
Statut: aheadofprint

Résumé

Sarcopenia is an acknowledged risk factor for individuals with chronic liver disease, however, the influence on outcomes in patients receiving transjugular intrahepatic portosystemic shunt (TIPS) remains underexplored. This study aimed to investigate the association between sarcopenia and incidence of complications and mortality post-TIPS. A retrospective analysis was performed on 175 patients who underwent TIPS between 2011-2021 at a Belgian tertiary care center. Transverse psoas muscle thickness (TPMT) was measured at baseline, with a subset of 85 patients having a second TPMT after 1-2 years for assessment of evolution. Over a median follow-up of 453 days (IQR 76-1179), sarcopenic patients exhibited a higher prevalence of complications (74.1% vs. 57.9%, p = 0.04) and one-year mortality (53.4% vs. 22.3%, p < 0.001) post-TIPS. Notably, 58.8% of patients showed an increase >10% from baseline TPMT/length post-TIPS, with the greatest improvement observed in severely sarcopenic patients (4.00 ± 4.55 mm/m vs. -0.82 ± 2.68 mm/m, p < 0.001) and in those patients free from TIPS-related complications (3.18 ± 4.09 mm/m vs. 1.31 ± 3.21 mm/m, p = 0.022). Sarcopenia increases the risk of complications and mortality post-TIPS. Importantly, sarcopenia improves in patients receiving TIPS, particularly in those with severe sarcopenia at baseline and free of TIPS-related complications.

Sections du résumé

BACKGROUND BACKGROUND
Sarcopenia is an acknowledged risk factor for individuals with chronic liver disease, however, the influence on outcomes in patients receiving transjugular intrahepatic portosystemic shunt (TIPS) remains underexplored.
AIMS OBJECTIVE
This study aimed to investigate the association between sarcopenia and incidence of complications and mortality post-TIPS.
METHODS METHODS
A retrospective analysis was performed on 175 patients who underwent TIPS between 2011-2021 at a Belgian tertiary care center. Transverse psoas muscle thickness (TPMT) was measured at baseline, with a subset of 85 patients having a second TPMT after 1-2 years for assessment of evolution.
RESULTS RESULTS
Over a median follow-up of 453 days (IQR 76-1179), sarcopenic patients exhibited a higher prevalence of complications (74.1% vs. 57.9%, p = 0.04) and one-year mortality (53.4% vs. 22.3%, p < 0.001) post-TIPS. Notably, 58.8% of patients showed an increase >10% from baseline TPMT/length post-TIPS, with the greatest improvement observed in severely sarcopenic patients (4.00 ± 4.55 mm/m vs. -0.82 ± 2.68 mm/m, p < 0.001) and in those patients free from TIPS-related complications (3.18 ± 4.09 mm/m vs. 1.31 ± 3.21 mm/m, p = 0.022).
CONCLUSION CONCLUSIONS
Sarcopenia increases the risk of complications and mortality post-TIPS. Importantly, sarcopenia improves in patients receiving TIPS, particularly in those with severe sarcopenia at baseline and free of TIPS-related complications.

Identifiants

pubmed: 39472174
pii: S1590-8658(24)01056-9
doi: 10.1016/j.dld.2024.10.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest None to report.

Auteurs

Emma Vanderschueren (E)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium; Department of Chronic Diseases, Metabolism and Aging (CHROMETA), Catholic University of Leuven, Herestraat 49, Leuven, Belgium. Electronic address: emma.vanderschueren@uzleuven.be.

Philippe Meersseman (P)

Department of General Internal Medicine, Medical Intensive Care Unit, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Alexander Wilmer (A)

Department of General Internal Medicine, Medical Intensive Care Unit, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Vincent Vandecaveye (V)

Department of Radiology, Abdominal Radiology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Evelyne Dubois (E)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Anne Van Eldere (A)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Jan Clerick (J)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Jo P Peluso (JP)

Department of Radiology, Interventional Radiology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Eveline Claus (E)

Department of Radiology, Interventional Radiology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Lawrence Bonne (L)

Department of Radiology, Interventional Radiology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Chris Verslype (C)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Geert Maleux (G)

Department of Radiology, Interventional Radiology, University Hospital Leuven, Herestraat 49, Leuven, Belgium.

Wim Laleman (W)

Department of Gastroenterology and Hepatology, University Hospital Leuven, Herestraat 49, Leuven, Belgium; Department of Chronic Diseases, Metabolism and Aging (CHROMETA), Catholic University of Leuven, Herestraat 49, Leuven, Belgium.

Classifications MeSH